Due to the shortage of available organs compared to the number of patients on waitlists, the organ allocation process has always been challenging and calls for an equitable and optimized allocation system. This system demands minimizing the waitlist mortality and improving transplantation...

Questo contributo analizza e commenta alcune tendenze recenti nella regolazione dei prezzi delle specialità medicinali. Il lavoro si concentra sulla crescente difficoltà nel riconciliare le richieste di prezzo per i farmaci maggiormente innovativi, sviluppati dalle imprese a valle di attività...

Das englische National Institute for Clinical Excellence (NICE) wird in der bundesdeutschen Diskussion um die Reform der Institutionen zur Konkretisierung des Leistungskatalogs in der GKV entweder als Vorbild oder als abschreckendes Beispiel genannt. Die Analyse der von NICE angewandten...

The aim of this article is to assess dilemma raised by adaptive preferences in the economic evaluation of growth hormone (GH) treatment for non-GH-deficient short children, and of bilateral cochlear implants for deaf children. Early implementation of both technologies and their irreversible...

There is a burgeoning literature in health economic evaluation, with this form of analysis becoming increasingly influential at the health policy making level in a number of countries. However, a search of the literature reveals that in Japan, the world's second largest health care market, very...

In attempting to constrain healthcare expenditure growth, health technology assessment (HTA) can enable policy-makers to look beyond budget impact and facilitate more rational decision-making. However lack of technical capacity and poor governance can limit use in some countries. Undertaking de...

European countries are increasingly utilising health technology assessment (HTA) to inform reimbursement decision-making. However, the current European HTA environment is very diverse, and projects are already underway to initiate a more efficient and aligned HTA practice within Europe. This...

Health technology assessment (HTA) is a dynamic, rapidly evolving process embracing different types of assessment that inform decisions about the value (i.e., benefits, risks and costs) of new and existing technologies. The role of HTA is to support health policy decision-making and financing in...

The College Voor Zorgverzekeringen (CVZ) provides guidance to the Dutch healthcare system on funding and use of new pharmaceutical technologies. This study examined the impact of evidence, process and context factors on CVZ decisions in 2004–2009. A data set of CVZ decisions pertaining to...

This paper describes and discusses the development and use of health technology assessment (HTA) in five Central and Eastern European countries (CEE): Poland, the Czech Republic, Hungary, Romania and Bulgaria. It provides a general snapshot of HTA policies in the selected CEE countries to date...